Our mission and values

Our mission

Blueprint Medicines aims to make real the promise of precision therapy to improve and extend life for as many people with cancer and hematologic disorders as possible.

Our core values

We strive to uphold our core values every day, and we recognize and celebrate these ideals together in many ways throughout the year.

Patients First

We maintain intense focus on improving patients’ lives

Thoughtfulness

We explore creative approaches, daring to make well-thought-out decisions and owning the outcomes

Urgency

We solve complex problems rapidly, with attention and care

Trust

We collaborate to build and maintain a cohesive team that leads with integrity as well as mutual respect of lived experiences, viewpoints and diverse talents

Optimism

We pursue transformative therapies that we believe will make a difference

We believe companies with diverse leadership are best positioned to fuel scientific and business innovation. We’ve made a
concerted effort to empower female and other diverse leaders to not only propel our business forward but also project their
leadership across the industry since our company's inception in 2011.

Learn more

Our story

2011

Led by the pioneers of highly successful kinase inhibitors including Gleevec® (imatinib), our scientific founders launched our company with a vision to revolutionize how kinase medicines are discovered and developed.

2011-2014

Our foundational work focused on the development of a proprietary library of novel compounds that are fully annotated against the human kinome. This library has become the basis for our successful drug discovery efforts.

2015

We launched an initial public offering on the Nasdaq stock exchange.

2015

We initiated clinical development of avapritinib in patients with advanced gastrointestinal stromal tumors and patients with systemic mastocytosis, and fisogatinib in patients with hepatocellular carcinoma.

2016

We entered into a global collaboration with Roche to develop up to five novel kinase medicines in the field of cancer immunotherapy.

2016

Clinical proof-of-concept data for avapritinib in patients with advanced gastrointestinal stromal tumors were reported at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics.

2017

We initiated clinical development of pralsetinib in patients with RET-altered cancers.

2017

Avapritinib received breakthrough therapy designation from the U.S. Food and Drug Administration for the treatment of unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA D842V mutation.

2017

Foundational preclinical data and clinical cases for avapritinib in advanced gastrointestinal stromal tumors were published in Science Translational Medicine.

2017

Preliminary Phase 1 clinical data for avapritinib in patients with advanced systemic mastocytosis were selected among more than 6,000 abstracts for presentation during the scientific plenary session at the American Society of Hematology annual meeting.

2018

Clinical proof-of-concept data for pralsetinib in patients with RET-altered cancers were reported at a clinical trials plenary session at the American Association for Cancer Research annual meeting and published in Cancer Discovery.

2018

We announced a strategic collaboration with CStone Pharmaceuticals to develop and commercialize avapritinib, fisogatinib and pralsetinib in Mainland China, Hong Kong, Macau and Taiwan.

2018

Avapritinib received breakthrough therapy designation from the U.S. Food and Drug Administration for the treatment of advanced systemic mastocytosis.

2019

Pralsetinib received breakthrough therapy designation from the U.S. Food and Drug Administration for the treatment of RET fusion-positive non-small cell lung cancer that has progressed following platinum-based chemotherapy, and RET mutation-positive MTC that requires systemic treatment and for which there are no acceptable alternative treatments.

2019

We submitted a new drug application to the U.S. Food and Drug Administration for avapritinib for the treatment of PDGFRA exon 18 mutant gastrointestinal stromal tumors (GIST) and fourth-line GIST.

2019

We announced an exclusive, worldwide license agreement with Ipsen for Clementia Pharmaceuticals, a subsidiary of Ipsen, to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva.

2020

We completed a rolling submission of a new drug application to the U.S. Food and Drug Administration for pralsetinib for the treatment of RET fusion-positive non-small cell lung cancer.

2020

We received approval of AYVAKIT™ (avapritinib) from the U.S. Food and Drug Administration for the treatment of PDGFRA exon 18 mutant gastrointestinal stromal tumors, including PDGFRA D842V mutations.

2020

We announced a global collaboration with Roche and Genentech, a member of the Roche Group, to develop and commercialize pralsetinib for patients with RET-altered cancers.

2020

We received a positive opinion from the Committee for Medicinal Products for Human Use for avapritinib for the treatment of adults with unresectable or metastatic PDGFRA D842V mutant gastrointestinal stromal tumors.

2020

We received accelerated approval of GAVRETO™ (pralsetinib) from the U.S. Food and Drug Administration for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

2020

We received conditional marketing authorization of AYVAKYT® (avapritinib) from the European Commission for the treatment of adults with unresectable or metastatic PDGFRA D842V mutant gastrointestinal stromal tumors.

2020

We received accelerated approval of GAVRETO™ (pralsetinib) from the U.S. Food and Drug Administration for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET-fusion positive thyroid cancer.

2020

We submitted a supplemental new drug application to the U.S. Food and Drug Administration for avapritinib for the treatment of patients with advanced systemic mastocytosis.

2021

We announced that avapritinib received breakthrough therapy designation from the U.S. Food and Drug Administration for the treatment of moderate to severe indolent systemic mastocytosis.

2021

The European Medicines Agency validated a Type II variation marketing authorization application for avapritinib for the treatment of advanced SM.

2021

We received approval of AYVAKIT™ (avapritinib) from the U.S. Food and Drug Administration for the treatment of advanced systemic mastocytosis, including aggressive SM, SM with an associated hematologic neoplasm and mast cell leukemia.

2022

We received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use for AYVAKYT® (avapritinib) for the treatment of adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm or mast cell leukemia, after at least one systemic therapy.

2022

We received marketing authorization of AYVAKYT® (avapritinib) from the European Commission for the treatment of adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm or mast cell leukemia, after at least one systemic therapy.